Aligos Therapeutics, Inc. expected to post a loss of $1.07 a share - Earnings Preview

Aligos Therapeutics

04/08/2026 15:38

Aligos Therapeutics, Inc. ALGS.OQ ALGS.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The South San Francisco California-based  company is expected to report a 1,790.5% increase in revenue to $18.243 million from $965 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Aligos Therapeutics, Inc. is for a loss of $1.07 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aligos Therapeutics, Inc. is $45.00, about 878.3% above its last closing price of $4.60
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-2.25
-2.22
-2.21
Beat
0.6
Dec. 31 2026
-2.32
-1.85
-1.91
Missed
-3.1
Sep. 30 2025
-1.91
-1.90
-3.04
Missed
-60​
Jun. 30 2025
-2.50
-2.36
-1.53
Beat
35.3
​​Mar. 31 2025
-2.74
-2.80
-2.11
Beat
24.6
Dec. 31 2024
-2.50
-3.40
Missed
-36.2​
Sep. 30 2024
-2.47
-2.16
-3.07
Missed
-42.3
Jun. 30 2024
-4.00
-4.00
0.80
Beat
120
This summary was machine generated August 4 at 14:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)